[e-farmacos] COX2 en el NEJM

["Canas, Martin" <macanas@netverk.com.ar>]

Estimadas y estimados,

El New England Journal of Medicine publica en forma adelantada 3 articulos originales y dos editoriales en relacion a los inhibidores COX2.

Articulos originales: 
Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention. S.D. Solomon and Others.
http://click.nejm.org/ct/click?q=70-3guJIdpCVDnHOj8WnRN4sQHjUJlqkEyR

Complications of the COX-2 Inhibitors Parecoxib and Valdecoxib after Cardiac Surgery. N.A. Nussmeier and Others:
http://click.nejm.org/ct/click?q=85-2DqoQ7KXfSHqyiw2fgwGVDCmBHsW2qPR

Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial. R.S. Bresalier and Others:
http://click.nejm.org/ct/click?q=9a-b0CGQTMEGYQww0Jvi79qyecTKzhemFrR

Editoriales
COX-2 Inhibitors - A Lesson in Unexpected Problems. J.M. Drazen:
http://click.nejm.org/ct/click?q=af-~RD8QLpbkxixu1zmdb_qN9JZVYde~MnR

COX-2 Inhibitors - Lessons in Drug Safety. B.M. Psaty and C.D. Furberg:
http://click.nejm.org/ct/click?q=c4-I4rlQ0WV9SlUNjFeHZt7~oyfx~p_wCFR

Saludos,

Martin

Martin Canas
GAPURMED
La Plata 
(Argentina)
macanas@netverk.com.ar